Bide Pharmatech (SH:688073) Sou Hu Cai Jing·2025-10-15 14:51Core Viewpoint - Bid Pharma (688073) is implementing foreign exchange hedging to mitigate currency fluctuation risks due to its import and export business primarily settled in foreign currencies [1] Group 1: Stock Performance - As of October 15, 2025, Bid Pharma's stock closed at 68.47 CNY, up 3.66% from the previous trading day, with a total market capitalization of 6.223 billion CNY [1] - The stock opened at 66.05 CNY, reached a high of 68.64 CNY, and a low of 65.21 CNY, with a trading volume of 50.0698 million CNY and a turnover rate of 1.71% [1] Group 2: Foreign Exchange Hedging Business - The company plans to conduct foreign exchange hedging with a maximum contract value of 600 million CNY on any trading day, and the margin and premium will not exceed 20 million CNY [1] - The hedging transactions will involve currencies such as USD, EUR, GBP, and HKD, utilizing methods including spot foreign exchange, forward foreign exchange, swaps, and options [1] - The board of directors has authorized the chairman or designated personnel to sign relevant documents within the approved limits, effective for 12 months from the board's approval [1] - The company has established a foreign exchange risk management system and implemented multiple risk control measures [1] - The matter has been approved by the 25th meeting of the second board of directors and does not require submission to the shareholders' meeting for approval [1] - The sponsor institution, Guotai Junan Securities, has no objections to the company's foreign exchange hedging business [1]